DK2121751T3 - Monoklonale antistoffer mod ANGPTL3 - Google Patents

Monoklonale antistoffer mod ANGPTL3 Download PDF

Info

Publication number
DK2121751T3
DK2121751T3 DK07862629.8T DK07862629T DK2121751T3 DK 2121751 T3 DK2121751 T3 DK 2121751T3 DK 07862629 T DK07862629 T DK 07862629T DK 2121751 T3 DK2121751 T3 DK 2121751T3
Authority
DK
Denmark
Prior art keywords
seq
set forth
antibody
leu
ser
Prior art date
Application number
DK07862629.8T
Other languages
English (en)
Inventor
E-Chiang Lee
Gregory Landes
Seokjoo Hong
Urvi Desai
David Powell
Xiao Feng
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2121751T3 publication Critical patent/DK2121751T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (16)

  1. PAT E NT K RAV
    1. Monoklonalt antistof, der binder til ANGPTL3 og formindsker niveauet af mindst et serumlipid in vivo, hvor det monoklonale antistof binder til en epitop af ANGPTL3, der har aminosyresekvensen af SEQ ID NO: 10.
  2. 2. Monoklonalt antistof ifølge krav 1, hvor det monoklonale antistof er et musemonoklonalt antistof, et humaniseret monoklonalt antistof eller et humant monoklonalt antistof.
  3. 3. Monoklonalt antistof ifølge krav 1, hvor det monoklonale antistof omfatter: • en variabel region af en tung kæde, omfattende aminosyresekvensen af SEQ ID NO: 20 og en variabel region af en let kæde, omfattende aminosyresekvensen af SEQ ID NO: 28; • en variabel region af en tung kæde, omfattende aminosyresekvensen af SEQ ID NO: 22 og en variabel region af en let kæde, omfattende aminosyresekvensen af SEQ ID NO: 30; • en variabel region af en tung kæde, omfattende aminosyresekvensen af SEQ ID NO: 24 og en variabel region af en let kæde, omfattende aminosyresekvensen af SEQ ID NO: 32; • en variabel region af en tung kæde, omfattende aminosyresekvensen af SEQ ID NO: 64 og en variabel region af en let kæde, omfattende aminosyresekvensen af SEQ ID NO: 68; eller • en variabel region af en tung kæde, omfattende aminosyresekvensen af SEQ ID NO: 66 og en variabel region af en let kæde, omfattende aminosyresekvensen af SEQ ID NO: 70.
  4. 4. Monoklonalt antistof ifølge krav 1, hvor det monoklonale antistof binder til den samme epitop som et antistof valgt fra listen bestående af: • et antistof, der omfatter en variabel region af en tung kæde, omfattende aminosyresekvensen af SEQ ID NO: 20 og en variabel region af en let kæde, omfattende aminosyresekvensen af SEQ ID NO: 28; • et antistof, der omfatter en variabel region af en tung kæde, omfattende aminosyresekvensen af SEQ ID NO: 22 og en variabel region af en let kæde, omfattende aminosyresekvensen af SEQ ID NO: 30; • et antistof, der omfatter en variabel region af en tung kæde, omfattende aminosyresekvensen af SEQ ID NO: 24 og en variabel region af en let kæde, omfattende aminosyresekvensen af SEQ ID NO: 32; • et antistof, der omfatter en variabel region af en tung kæde, omfattende aminosyresekvensen af SEQ ID NO: 64 og en variabel region af en let kæde omfattende aminosyresekvensen af SEQ ID NO: 68; eller • et antistof, der omfatter en variabel region af en tung kæde, omfattende aminosyresekvensen af SEQ ID NO: 66 og en variabel region af en let kæde, omfattende aminosyresekevnsen af SEQ ID NO: 70.
  5. 5. Monoklonalt antistof ifølge krav 1 eller krav 4, hvor den tunge kæde omfatter • en CDR1 som angivet i SEQ ID NO: 35, en CDR2 som angivet i SEQ ID NO: 36 og en CDR3 som angivet i SEQ ID NO: 37; • en CDR1 som angivet i SEQ ID NO: 38, en CDR2 som angivet i SEQ ID NO: 39 og en CDR3 som angivet i SEQ ID NO: 40; • en CDR1 som angivet i SEQ ID NO: 41, en CDR2 som angivet i SEQ ID NO: 42 og en CDR3 som angivet i SEQ ID NO: 43; • en CDR1 som angivet i SEQ ID NO: 53, en CDR2 som angivet i SEQ ID NO: 54 og en CDR3 som angivet i SEQ ID NO: 55; • en CDR1 som angivet i SEQ ID NO: 71, en CDR2 som angivet i SEQ ID NO: 72 og en CDR3 som angivet i SEQ ID NO: 73; eller • en CDR1 som angivet i SEQ ID NO: 74, en CDR2 som angivet i SEQ ID NO: 75 og en CDR3 som angivet i SEQ ID NO: 76.
  6. 6. Monoklonalt antistof ifølge krav 5, hvor • den tunge kæde omfatter en CDR1 som angivet i SEQ ID NO: 35, en CDR2 som angivet i SEQ ID NO: 36 og en CDR3 som angivet i SEQ ID NO: 37; og den lette kæde omfatter en CDR1 som angivet i SEQ ID NO: 44, en CDR2 som angivet i SEQ ID NO: 45 og en CDR3 som angivet i SEQ ID NO: 46; • den tunge kæde omfatter en CDR1 som angivet i SEQ ID NO: 38, en CDR2 som angivet i SEQ ID NO: 39 og en CDR3 som angivet i SEQ ID NO: 40; og den lette kæde omfatter en CDR1 som angivet i SEQ ID NO: 47, en CDR2 som angivet i SEQ ID NO: 48 og en CDR3 som angivet i SEQ ID NO: 49; • den tunge kæde omfatter en CDR1 som angivet i SEQ ID NO: 41, en CDR2 som angivet i SEQ ID NO: 42 og en CDR3 som angivet i SEQ ID NO: 43; og den lette kæde omfatter en CDR1 som angivet i SEQ ID NO: 50, en CDR2 som angivet i SEQ ID NO: 51 og en CDR3 som angivet i SEQ ID NO: 52; • den tunge kæde omfatter en CDR1 som angivet i SEQ ID NO: 53, en CDR2 som angivet i SEQ ID NO: 54 og en CDR3 som angivet i SEQ ID NO: 55; og den lette kæde omfatter en CDR1 som angivet i SEQ ID NO: 56, en CDR2 som angivet i SEQ ID NO: 57 og en CDR3 som angivet i SEQ ID NO: 58; • den tunge kæde omfatter en CDR1 som angivet i SEQ ID NO: 71, en CDR2 som angivet i SEQ ID NO: 72 og en CDR3 som angivet i SEQ ID NO: 73; og den lette kæde omfatter en CDR1 som angivet i SEQ ID NO: 77, en CDR2 som angivet i SEQ ID NO: 78 og en CDR3 som angivet i SEQ ID NO: 79; eller • den tunge kæde omfatter en CDR1 som angivet i SEQ ID NO: 74, en CDR2 som angivet i SEQ ID NO: 75 og en CDR3 som angivet i SEQ ID NO: 76; og den lette kæde omfatter en CDR1 som angivet i SEQ ID NO: 80, en CDR2 som angivet i SEQ ID NO: 81 og en CDR3 som angivet i SEQ ID NO: 82.
  7. 7. Monoklonalt antistof ifølge krav 1 eller krav 4, hvor den lette kæde omfatter • en CDR1 som angivet i SEQ ID NO: 44, en CDR2 som angivet i SEQ ID NO: 45 og en CDR3 som angivet i SEQ ID NO: 46; • en CDR1 som angivet i SEQ ID NO: 47, en CDR2 som angivet i SEQ ID NO: 48 og en CDR3 som angivet i SEQ ID NO: 49; • en CDR1 som angivet i SEQ ID NO: 50, en CDR2 som angivet i SEQ ID NO: 51 og en CDR3 som angivet i SEQ ID NO: 52; • en CDR1 som angivet i SEQ ID NO: 56, en CDR2 som angivet i SEQ ID NO: 57 og en CDR3 som angivet i SEQ ID NO: 58; • en CDR1 som angivet i SEQ ID NO: 77, en CDR2 som angivet i SEQ ID NO: 78 og en CDR3 som angivet i SEQ ID NO: 79; eller • en CDR1 som angivet i SEQ ID NO: 80, en CDR2 som angivet i SEQ ID NO: 81 og en CDR3 som angivet i SEQ ID NO: 82.
  8. 8. Monoklonalt antistof ifølge et hvilket som helst af kravene 5, 6 eller 7, hvor antistoffet er et musemonoklonalt antistof; eller et humaniseret monoklonalt antistof.
  9. 9. Monoklonalt antistof ifølge et hvilket som helst af kravene 1,5, 6 eller 7, hvor antistoffet er et antistoffragment.
  10. 10. Monoklonalt antistof ifølge krav 9, hvor antistoffragmentet er et scFv-fragment, et Fab-fragment, et Fab'-fragment eller et F(ab')2-fragment.
  11. 11. Monoklonalt antistof ifølge krav 1, hvor antistoffets affinitet til et peptid med en aminosyresekvens af SEQ ID NO: 10 er mindst 3 gange større end antistoffets affinitet til et peptid med en aminosyresekvns af en hvilken som helst af SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 90 og SEQ ID NO: 92.
  12. 12. Monoklonalt antistof ifølge krav 11, hvor antistoffets affinitet til et peptid med en aminosyresekvens af SEQ ID NO: 10 er mindst 3 gange større end antistoffets affinitet til hver af SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88 og SEQ ID NO: 90.
  13. 13. Monoklonalt antistof ifølge krav 1, hvor antistoffet binder til et peptid med aminosyresekvensen af SEQ ID NO: 10 med en Kd på: mindre end 50 nM; mindre end 30 nM; mindre end 10 nM; eller mindre end 5 nM, hvor the Kd måles med BIACORE.
  14. 14. Farmaceutisk sammensætning omfattende det monoklonale antistof ifølge et hvilket som helst af kravene 1-13.
  15. 15. Anvendelse af den farmaceutiske sammensætning ifølge krav 14 til fremstilling af et lægemiddel til behandling af en forstyrrelse af lipid metabolisme, hypertriglyceridæmi, hyperkolesterolæmi, fedme, diabetes, iskæmisk hjertelidelse eller metabolisk syndrom eller til formindskelse af niveauet af et eller flere serumlipider.
  16. 16. Farmaceutisk sammensætning ifølge krav 14 til anvendelse i fremgangsmåde til behandling af en forstyrrelse af lipid metabolisme, hypertriglyceridæmi, hyperkolesterolæmi, fedme, diabetes, iskæmisk hjertelidelse eller metabolisk syndrom eller til formindskelse af niveauet af et eller flere serumlipider.
DK07862629.8T 2006-12-08 2007-12-06 Monoklonale antistoffer mod ANGPTL3 DK2121751T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87383406P 2006-12-08 2006-12-08
PCT/US2007/025080 WO2008073300A2 (en) 2006-12-08 2007-12-06 Monoclonal antibodies against angptl3

Publications (1)

Publication Number Publication Date
DK2121751T3 true DK2121751T3 (da) 2017-04-24

Family

ID=39512267

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07862629.8T DK2121751T3 (da) 2006-12-08 2007-12-06 Monoklonale antistoffer mod ANGPTL3

Country Status (21)

Country Link
US (2) US7935796B2 (da)
EP (1) EP2121751B1 (da)
JP (1) JP5484063B2 (da)
KR (1) KR101503937B1 (da)
CN (1) CN101855241B (da)
AR (1) AR064205A1 (da)
AU (1) AU2007332855B2 (da)
BR (1) BRPI0720218A2 (da)
CA (1) CA2672049C (da)
DK (1) DK2121751T3 (da)
EA (1) EA019661B1 (da)
ES (1) ES2618830T3 (da)
HU (1) HUE033960T2 (da)
IL (1) IL199216A (da)
MX (1) MX2009006082A (da)
NO (1) NO20092215L (da)
PL (1) PL2121751T3 (da)
PT (1) PT2121751T (da)
TW (1) TW200846364A (da)
WO (1) WO2008073300A2 (da)
ZA (1) ZA200904022B (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672049C (en) * 2006-12-08 2016-05-10 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
US8802646B2 (en) 2008-10-08 2014-08-12 Trustees Of Dartmouth College Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease
WO2010042292A1 (en) * 2008-10-08 2010-04-15 Trustees Of Dartmouth College Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease
US9388413B2 (en) 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
US9388414B2 (en) 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
US9149492B2 (en) 2008-10-08 2015-10-06 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
CN101852805B (zh) * 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
AU2011203986C1 (en) * 2010-01-08 2015-03-05 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
AU2015200969A1 (en) * 2010-01-08 2015-03-19 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
CA2791658C (en) * 2010-03-04 2019-10-01 Macrogenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012109282A2 (en) * 2011-02-07 2012-08-16 Agamin Pharmaceuticals, Llc Methods and systems for treating or preventing pregnancy-related hypertensive disorders
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
AU2012272970A1 (en) * 2011-06-21 2014-02-06 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
US20180009888A9 (en) 2011-06-23 2018-01-11 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2756004B1 (en) 2011-09-16 2019-12-25 Regeneron Pharmaceuticals, Inc. INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
JP6154900B2 (ja) 2012-07-13 2017-06-28 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
WO2014052672A1 (en) 2012-09-27 2014-04-03 Biocare Medical, Llc Anti-uroplakin ii antibodies systems and methods
GB201219487D0 (en) * 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
JP6445467B2 (ja) 2013-02-28 2019-01-09 バイオケア メディカル， エルエルシー 抗ｐ４０抗体システムおよび方法
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
IL284593B2 (en) 2013-05-01 2023-02-01 Ionis Pharmaceuticals Inc Compositions and methods for modulation of hbv and ttr expression
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
ES2765423T3 (es) 2013-10-03 2020-06-09 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti-SOX10
ES2754209T3 (es) * 2013-12-13 2020-04-16 Stora Enso Oyj Cartón multicapa
WO2015100394A1 (en) * 2013-12-24 2015-07-02 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
EP3137605B1 (en) 2014-05-01 2020-10-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
WO2015184105A1 (en) 2014-05-29 2015-12-03 Trustees Of Dartmouth College Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases
US9527922B2 (en) * 2014-12-31 2016-12-27 Development Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
CA2982450A1 (en) 2015-04-13 2016-10-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
WO2017079739A1 (en) 2015-11-06 2017-05-11 Ionis Pharmaceuticals, Inc. MODULATING APOLIPOPROTEIN (a) EXPRESSION
CN108697797A (zh) * 2016-02-17 2018-10-23 瑞泽恩制药公司 通过施用angptl3的抑制剂治疗或预防动脉粥样硬化的方法
SG11201808979UA (en) 2016-04-15 2018-11-29 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
EP3448426A1 (en) * 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods for treating patients with familial hypercholesterolemia
CA3042236A1 (en) 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
CN107085112B (zh) * 2017-05-10 2019-03-19 武汉圣润生物科技有限公司 一种用于检测白血病的试剂盒
EP3774916A2 (en) * 2018-04-06 2021-02-17 Biolegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US20200369760A1 (en) 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
CN112062845B (zh) * 2019-06-10 2022-09-02 山东博安生物技术股份有限公司 Angptl3结合片段及其用途
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
JP2023510787A (ja) * 2020-01-22 2023-03-15 江蘇恒瑞医薬股▲ふん▼有限公司 抗ａｎｇｐｔｌ３抗体及びその応用
WO2022109443A1 (en) * 2020-11-23 2022-05-27 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
WO2022187435A1 (en) 2021-03-04 2022-09-09 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
US20240141029A1 (en) * 2021-03-05 2024-05-02 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
JPWO2022244845A1 (da) * 2021-05-19 2022-11-24
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3226367A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3226365A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3225970A1 (en) * 2021-07-21 2023-01-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
CN116284377A (zh) * 2021-12-21 2023-06-23 复旦大学 抗人血管生成素3纳米抗体及其应用
US11780910B1 (en) 2022-05-02 2023-10-10 Novo Nordisk A/S Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
CN117447592A (zh) * 2022-07-26 2024-01-26 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用
CN116199779B (zh) * 2022-12-08 2023-08-11 北京东方百泰生物科技股份有限公司 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5912000A (en) 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW313568B (da) 1994-12-20 1997-08-21 Hoffmann La Roche
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US20030100051A1 (en) 1998-05-12 2003-05-29 Ruben Steven M. 97 human secreted proteins
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
CN1433482A (zh) 1999-12-09 2003-07-30 三共株式会社 高脂血症的治疗或预防剂的检验方法
CA2450022A1 (en) * 2001-06-08 2002-12-19 Sankyo Company, Limited Method of testing drug for treating or preventing diseases such as hyperlipemia
MXPA04004609A (es) * 2001-11-16 2004-08-12 Genentech Inc Composicion que comprende y metodo para utilizar angptl3 de proteina 3 como angiopoyetina.
KR101387781B1 (ko) 2005-01-07 2014-04-21 렉시컨 파마슈티컬스 인코퍼레이티드 앤지오포이에틴-유사 단백질 4 (ａｎｇｐｔｌ４) 에 대한단일클론 항체
CA2672049C (en) * 2006-12-08 2016-05-10 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3

Also Published As

Publication number Publication date
AU2007332855A1 (en) 2008-06-19
AU2007332855B2 (en) 2012-08-16
ZA200904022B (en) 2010-08-25
JP2010512320A (ja) 2010-04-22
PL2121751T3 (pl) 2017-07-31
US8742075B2 (en) 2014-06-03
NO20092215L (no) 2009-08-19
WO2008073300A2 (en) 2008-06-19
CN101855241B (zh) 2013-11-06
EA200970556A1 (ru) 2010-04-30
BRPI0720218A2 (pt) 2013-12-24
KR101503937B1 (ko) 2015-03-18
US20110243948A1 (en) 2011-10-06
CA2672049C (en) 2016-05-10
ES2618830T3 (es) 2017-06-22
EA019661B1 (ru) 2014-05-30
CN101855241A (zh) 2010-10-06
KR20090088925A (ko) 2009-08-20
AR064205A1 (es) 2009-03-18
US7935796B2 (en) 2011-05-03
WO2008073300A3 (en) 2009-12-23
EP2121751B1 (en) 2017-01-25
HUE033960T2 (en) 2018-01-29
EP2121751A2 (en) 2009-11-25
TW200846364A (en) 2008-12-01
IL199216A (en) 2016-02-29
PT2121751T (pt) 2017-04-18
US20080177045A1 (en) 2008-07-24
JP5484063B2 (ja) 2014-05-07
CA2672049A1 (en) 2008-06-19
EP2121751A4 (en) 2012-01-11
MX2009006082A (es) 2009-08-18

Similar Documents

Publication Publication Date Title
DK2121751T3 (da) Monoklonale antistoffer mod ANGPTL3
EP1846452B1 (en) Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )
EA035088B1 (ru) Анти-angptl8 антитела и их применение
KR102573257B1 (ko) 섬유증의 치료를 위한 항-fam19a5 항체의 용도
MX2010009185A (es) Anticuerpos dirigidos a la angiopoietina-1 y la angiopoietina-2 y uso de los mismos.
JP2022526487A (ja) Ｖｅｇｆ及びａｎｇ２に特異的に結合する二重特異性抗体
AU2017254775A1 (en) Method of treating or preventing liver conditions
JP2012504946A (ja) 血小板第４因子変異体１（ｐｆ４ｖ１）に対する中和抗体およびそのフラグメント
WO2018035119A9 (en) Methods of treating cancer using bifunctional molecules that target growth factors
US20240132604A1 (en) Chemokine receptor 8 (ccr8) antibodies
WO2024086684A2 (en) Chemokine receptor 8 (ccr8) antibodies